Amitone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amitone

Property Description
Active ingredient Ketotifen Fumarate (INN)
Form Ophthalmic Solution (Eye Drops) and Oral Dosage Forms (Tablets, Syrup)
Pharmacological class H₁-receptor Antagonist and Mast Cell Stabilizer
Common use General prophylaxis and relief of allergic symptoms
Origin Synthetic organic compound

What Type of Medicine is Amitone (Ketotifen Fumarate)?

Amitone is defined as a specialized anti-allergic agent whose active component, Ketotifen Fumarate, functions simultaneously as a relatively selective Histamine H₁-receptor Antagonist and, concurrently, as a Mast Cell Stabilizer. This unique, dual-action classification differentiates it from many standard antihistamines which lack the cell-stabilizing property. The active moiety, Ketotifen, is a synthetic organic compound—a benzocycloheptathiophene derivative—first developed to address allergic processes at a cellular level.

The Active Component and Forms of Amitone

The drug contains Ketotifen Fumarate as its single active ingredient. This compound is formulated for various routes of administration, reflecting its use for both localized and systemic allergic issues. It is prepared as a sterile ophthalmic solution for targeted topical application to the eye, utilizing an aqueous solution as its base, and as various oral dosage forms, including tablets and syrup. The availability of Ketotifen Fumarate across these forms enables it to address different manifestations of allergic conditions.

General Purpose and Benefit of this Dual-Action Agent

The purpose of Amitone is to provide integrated and sustained relief from allergic manifestations through its dual mode of action. By directly blocking the H₁ receptors, it limits the immediate effects of released histamine, mitigating symptoms like itching. Simultaneously, by stabilizing mast cells, it offers a pre-emptive benefit by preventing the release of other potent inflammatory chemicals, such as leukotrienes. This combined action means the medication is designed to address a typical use scenario where patients seek relief from the chronic or recurrent inflammation caused by allergies, resulting in a reduction of symptom severity and frequency.

What side effects are possible with Amitone?

Possible Side Effects and Safety Information

The official safety profile for Amitone (Ketotifen Fumarate) is organized based on government regulatory standards, classifying adverse reactions by frequency and the physiological system affected. This classification system differentiates between common, less severe effects and rare, serious adverse reactions.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions, classified as Common in regulatory documents, include local effects such as eye irritation, eye pain, and punctate corneal epithelial erosion (with ophthalmic use). Systemic effects classified as Common include somnolence (drowsiness), headache, and dry mouth. Less frequent reactions, classified as Uncommon, include blurred vision during instillation, rash, and dizziness.

Systemic and Serious Adverse Events

Adverse reactions are grouped into standard System-Organ Classes. For the oral forms, effects are listed under Nervous System Disorders (headache, somnolence) and Gastrointestinal Disorders (dry mouth, abdominal pain). Immune System Disorders include the risk of hypersensitivity and systemic allergic reactions, which have been noted in post-marketing reports (frequency not known).

Serious adverse reactions documented in regulatory sources, often associated with overdose, include severe Central Nervous System events such as convulsions, confusion, and tachycardia. Official labeling notes that oral forms may potentiate the effects of CNS depressants, alcohol, and other antihistamines.

Population and Exposure-Related Safety Notes

Official prescribing information includes specific safety considerations for defined groups. For the ophthalmic solution, safety has not been established in children under 3 years of age. For oral forms, CNS stimulation (irritability, excitement) is noted as more likely in children. Furthermore, the label notes that somnolence associated with oral use may decrease over time with long-term administration, establishing a time-related safety pattern for the medicine.

Overdose and Emergency Response

Overexposure to Amitone (Ketotifen Fumarate) is officially documented in regulatory information to primarily affect the central nervous and cardiovascular systems. Immediate medical attention must be sought if an overdose is suspected, or if oral solution contents are accidentally swallowed. The official label mandates that a Poison Control Center be contacted right away.

Documented manifestations of overdosage include significant CNS depression, presenting as severe sedation, drowsiness, confusion, and disorientation. In severe cases, the regulatory profile lists the potential for convulsions and reversible coma. Cardiovascular signs such as tachycardia (fast heart rate) and hypotension (low blood pressure) are also documented. A specific consideration noted in official labeling is that hyperexcitability may occur particularly in children.

Because no specific antidote is known, treatment is officially described as symptomatic and supportive. Regulatory documents detail potential procedural steps, including considering gastric lavage and administration of activated charcoal if ingestion is recent. Supportive measures may also include the use of short-acting barbiturates or benzodiazepines to manage excitation or convulsions, and Physostigmine to mitigate associated anticholinergic effects. Hospital observation may be required to manage these severe symptoms.

Therapeutic Uses of Amitone

What Amitone Treats: Main Uses and Benefits

The primary role of Amitone (Ketotifen Fumarate) is to support symptomatic management across key domains of allergic disease, with relevance in situations involving supportive symptom management. The medication is generally used to help relieve symptoms associated with allergic processes, particularly those involving heightened physiological activity.


Key Therapeutic Applications

A key patient-oriented benefit is supporting patients during difficult episodes by easing distress and helping manage symptom clusters that may become intense or disruptive. Amitone is commonly applied in clinical settings that involve recurrent or episodic manifestations, including allergic conjunctivitis, allergic rhinitis (hay fever), and the long-term maintenance of symptoms in specific forms of bronchial asthma and chronic urticaria (hives).

“The medication is commonly used to help with conditions where symptoms may intensify temporarily, applied in scenarios where additional management of discomfort is required.”


Therapeutic Summary

  • Sustained Control: Applied in conditions characterized by periods of heightened symptoms, helping manage the overall symptom load related to chronic skin and nasal allergies.
  • Respiratory Support: Plays a role in managing symptoms of mild atopic asthma by helping stabilize the underlying airway condition.
  • Ocular Relief: Used when localized allergic symptoms, like tearing and redness, create noticeable physiological strain.
Quick Fact: Relief for Pruritus
Provides supportive relief for itching (pruritus) associated with systemic and ocular allergic conditions, particularly symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview of Ketotifen

Eligibility and Restrictions for Use

Who can and cannot use Amitone?

Official regulatory documents define specific population eligibility rules for using Amitone (Ketotifen Fumarate), which vary by dosage form.


Absolute Contraindications

Amitone is strictly contraindicated for individuals with a known hypersensitivity or allergy to Ketotifen or any excipients in the product formulation. For the systemic (oral) forms, international labeling states that use is prohibited in patients concurrently receiving oral antidiabetic agents and is contraindicated for breastfeeding mothers.


Age-Group and Conditional Use

The ophthalmic solution is approved for use in adults and children 3 years of age and older. Safety and effectiveness have not been established for children under the age of three years. Contact lens wearers must adhere to a conditional use restriction by removing soft contact lenses before instillation and waiting at least ten minutes before reinsertion. Additionally, the oral forms are generally not recommended for patients with a history of epilepsy or seizure disorders.


Reproductive Status

The ophthalmic solution is classified as Pregnancy Category C. Use during pregnancy is advised only if clearly needed due to limited human data. Caution should be exercised when the ophthalmic solution is administered to a nursing mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Amitone (Ketotifen Fumarate) is defined by its pharmacodynamic effects and specific administrative constraints, as documented in government regulatory labeling.


Drug and Substance Interactions

Co-administration of the oral dosage form with substances that cause Central Nervous System (CNS) depression, including sedatives, hypnotics, other antihistamines, and alcohol, may result in the potentiation of the depressant effects. This additive pharmacodynamic action leads to an increased level of CNS depression.

A distinct, outcome-based interaction is documented with Oral Antidiabetic Agents. Regulatory sources report rare cases of a reversible fall in thrombocyte count in patients taking these medicines concomitantly with oral Ketotifen. This documented risk necessitates the mandatory monitoring of platelet counts for affected patients.


Ophthalmic and Administration Constraints

For the ophthalmic solution, specific administration constraints are required. If other ophthalmic medications (drops or ointments) are used, a minimum separation interval of at least 5 minutes between applications is mandated. Furthermore, soft contact lenses must be removed before the administration of the eye drops, and reinsertion must be delayed by 10 minutes, due to the potential for absorption of the preservative component.

The carbohydrate content of the syrup formulation is also a documented consideration for patients with Diabetes Mellitus who are adhering to a specific diet.

Mechanism of Action

Amitone operates via a combination of three distinct mechanisms. Primarily, it functions as an inhibitor of the Serotonin and Norepinephrine Transporters, preventing the rapid reabsorption of these neurotransmitters and increasing their concentration in the synaptic space. This action contributes to a sustained change in signaling dynamics within monoaminergic pathways of the central nervous system. Secondarily, the drug acts as a modulator of voltage-gated sodium channels, thereby reducing the electrical excitability of neuronal membranes. This modulation decreases the frequency of nerve firing, which reduces the transmission of excessive nerve signals within various neural pathways. Lastly, Amitone exhibits antagonism at multiple receptor sites, including Histamine H1 and Muscarinic receptors. This interference results in central nervous system depression and alters involuntary bodily functions, such as smooth muscle tone and glandular activity.

Dosage and Administration Information

How to Use Amitone (Ketotifen Fumarate): Official Administration Guidelines

The usage of Ketotifen Fumarate is defined by its two official routes of administration: oral for systemic action and ophthalmic for localized treatment of the eyes. Both forms follow a standardized twice-daily schedule to maintain consistent drug levels.


Oral Administration Protocol

The standard maintenance regimen for adult oral use is 1 mg of Ketotifen (base) taken twice daily, typically once in the morning and once in the evening. In situations requiring greater systemic exposure, the dose may be increased to 2 mg twice daily.

Contextual Requirements: The oral tablets or syrup are intended to be consumed with food to align with established administration conditions. Initial oral treatment may involve a lower evening dose of 0.5 mg to 1 mg for the first few days for those prone to sedation before transitioning to the twice-daily schedule.

Course Duration and Discontinuation: Oral Ketotifen is a prophylactic agent intended for continuous use. Because its full therapeutic effect may take up to several weeks to manifest, treatment is often maintained for a minimum of two to three months. Discontinuation of long-term oral therapy is performed gradually over a period of two to four weeks. If a dose is missed, the next dose is taken at the regularly scheduled time; the dose is not doubled.


Ophthalmic Administration Protocol

The standard administration for the ophthalmic solution is one drop in the affected eye(s) twice daily. These doses are typically separated by an interval of 8 to 12 hours.

Pediatric Dosing: For children three years of age and older, the oral and ophthalmic doses are the same as the adult dose. For younger children, six months to three years, the oral dose is calculated based on body weight: 0.05 mg/kg twice daily.

Special Procedural Condition: Soft contact lenses are removed before administering the eye drops, and a wait of 10 minutes is observed following the dose before lenses are reinserted.

Recent Clinical Evidence

Research evidence / Overview of studies for Amitone

Evidence for Use in Allergic Conjunctivitis (Eye Drops)

The research for the ophthalmic solution primarily consists of short-term, double-blind randomized controlled trials (RCTs) and studies utilizing a standardized Allergen Challenge Model. These trials monitored outcomes related to physical discomfort, such as patient-reported scores for ocular itching, redness, and tearing. Findings describe patterns of change in itching scores observed in the studies that were statistically distinguishable from the placebo (inactive vehicle).

Research indicates that patterns of change in itching scores were observed quickly, with the measured outcomes remaining distinguishable from placebo across several hours of observation after a single dose. However, existing studies provide limited insight into continuous use and long-term ocular health effects beyond four weeks.

Evidence for Use in Chronic Urticaria and Allergic Rhinitis (Oral Forms)

Amitone was studied for conditions characterized by fluctuating or episodic manifestations, such as chronic urticaria (hives) and allergic rhinitis (hay fever). Studies monitored outcomes describing perceived discomfort related to pruritus and the size and number of wheals for urticaria, and nasal changes for rhinitis.

Findings related to the change in scores for itching and rash severity in some trials were described as having no significant differences when compared to placebo in short-term studies, while other long-term studies reported measurements that were statistically distinguishable from baseline measurements. The supporting data for some of these systemic indications often relies on older research, contributing to a lower certainty about findings. Comparative evidence is also lacking in recent large-scale RCTs against newer treatments.

Evidence for Use in Long-Term Asthma Management (Oral Forms)

Amitone was evaluated in clinical trials and systematic reviews, primarily for its systemic use in the long-term management of mild to moderate atopic asthma, particularly in children. Research examined patient capacity to change the use of bronchodilators (rescue medication), frequency of asthma exacerbations, and overall symptom control.

Systematic reviews reported patterns observed in studies where a higher proportion of subjects was observed to have a change in the use of other asthma medications compared to placebo groups. However, many trials were conducted before modern inhaled corticosteroids became standard maintenance treatment. Therefore, the results reflect the specific conditions under which they were conducted, and data are still emerging regarding its role when used alongside current widely accepted standard therapies.

What Remains Uncertain and Areas for Further Research

Research has explored outcomes in both adults and pediatric subjects, but data for certain groups, such as older adults with multiple comorbidities, remain insufficient. The long-term effects are not fully established for continuous use spanning many months or years, especially regarding the durability of the measured effects and whether individual responses are maintained over time. Research is ongoing to better contextualize how these findings contribute to the broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Amitone (FAQ)


Q: What are the main health conditions Amitone is officially approved to treat?

Official approvals for Amitone (Ketotifen Fumarate) differ depending on the dosage form and the country. The ophthalmic solution is widely approved for the temporary relief of itchy eyes due to allergic conjunctivitis. Oral forms have been indicated in some regions for the management of chronic allergic asthma, chronic urticaria (hives), and allergic rhinitis.


Q: Is Amitone a brand-name drug, or is a generic equivalent available?

Amitone is the invented name for the active ingredient Ketotifen Fumarate. This medicine is available under various brand names around the world. Regulatory agencies have also approved lower-cost generic versions of the ophthalmic solution for sale.


Q: How is the purpose of Amitone described in patient information leaflets?

Patient information sheets often describe the ophthalmic solution simply as an antihistamine eye drop. Its purpose is to temporarily relieve eye itching caused by common allergens like pollen, pet dander, or dust. Oral forms are generally described as a prophylactic (preventive) agent for various chronic allergic conditions.


Q: Are there any secondary or alternate approved uses for Amitone?

Yes, official regulatory monographs indicate that while the ophthalmic solution is for localized eye allergy symptoms, the oral forms have systemic uses. In some regions, the oral dosage is specifically indicated for the long-term control of chronic allergic asthma and the treatment of chronic urticaria (hives).


Q: How is Amitone chemically or functionally different from other common treatments for the same condition?

Official drug classifications indicate that Ketotifen Fumarate has a dual mode of action, which differentiates it from many standard antihistamines. It functions both as a histamine H₁-receptor antagonist (blocking the immediate allergic reaction) and as a mast cell stabilizer (preventing inflammatory chemicals from being released).


Q: How long does it typically take for a patient to feel the intended effects of Amitone?

The onset of effect depends on the form used. For the ophthalmic eye drops, relief from itchy eyes typically begins within minutes of administration. For the oral forms, the medication works preventively, meaning the full therapeutic benefit may take several weeks to manifest with continuous use.


Q: What research evidence exists regarding the expected duration of Amitone's effects?

Official clinical studies for the ophthalmic solution show that the anti-itch effect can last for several hours after a single dose. For the long-term oral forms, official research summaries note that the durability of the measured effects over continuous use is still an area being investigated.


Q: Does taking Amitone cause changes in a patient's energy levels or appetite?

Regulatory documents list common side effects that can affect energy and appetite. Somnolence (drowsiness) is reported as a side effect and may affect energy levels. Increased appetite is also documented as a possible side effect in some official adverse reaction lists.


Q: What is the official definition of a serious adverse event related to Amitone?

Official regulatory documents list examples of serious adverse reactions, such as severe allergic responses or convulsions. A Serious Adverse Event is generally defined by regulators as an experience that requires specific medical intervention, such as hospitalization, or results in a life-threatening outcome, death, or persistent disability.


Q: What are the official sources for checking the efficacy and safety data on Amitone?

Patients can access the full regulatory data by searching for the active ingredient, Ketotifen Fumarate, on government websites. The official prescribing information, safety data, and the FDA Label or European Summary of Product Characteristics (SmPC) are typically available through national regulatory databases like DailyMed or the European Medicines Agency (EMA).


Q: How long does the body typically take to clear Amitone after the last dose?

Official pharmacokinetic summaries indicate that the drug is cleared from the body in two phases after oral administration. Regulatory documents report the terminal half-life of Ketotifen (a measure of drug clearance) is approximately 12 hours.


Q: Are there any known long-term side effects or safety concerns associated with using Amitone?

The long-term effects of continuous use over many months or years are not fully established in research. One time-related safety pattern noted is that the drowsiness associated with the oral form may decrease over time with continued administration.


Q: Is weight change mentioned as a possible side effect in the official documentation for Amitone?

Yes, official adverse reaction reports include 'Weight increased' and 'Increased appetite' as possible side effects. These reactions are generally not listed among the most commonly reported adverse events.


Q: How does the risk of side effects compare between older adults and younger patients taking Amitone?

Official regulatory information notes specific differences based on age. For children, the oral form is noted to be more likely to cause central nervous system stimulation, such as irritability or excitement. Research summaries indicate that data on older adults with multiple pre-existing conditions remains insufficient for a comprehensive risk profile.


Q: What are general warning signs of a mild drug interaction involving Amitone?

Official prescribing information notes that Amitone can enhance the effects of Central Nervous System (CNS) depressants, such as sedatives or alcohol. Warning signs of this interaction may include increased drowsiness, sedation, or impaired mental and physical alertness.


Q: What is the FDA or EMA's official safety classification of Amitone?

Official regulatory bodies generally do not assign a single, simple overall safety rating to medicines. Instead, the safety profile is classified by the frequency of reported adverse events (Common, Uncommon, etc.) and by risk to specific populations, such as the Pregnancy Category C classification.


Q: Are there any specific foods or beverages, such as grapefruit, that should be avoided while taking Amitone?

Regulatory guidance for the oral form recommends that the medication be consumed with food. The syrup formulation’s carbohydrate content is noted as a necessary consideration for patients with Diabetes Mellitus. There is no official interaction warning documented for specific foods like grapefruit.


Q: Are there specific warnings or precautions listed for older adult patients taking Amitone?

Official research summaries indicate that data on older adults, particularly those with multiple chronic illnesses, remains insufficient to fully establish a comprehensive safety profile. This lack of specific data is noted as a caution when considering use in this population.


Q: What clinical research themes are currently being explored for Amitone?

Official research summaries indicate that areas for further investigation include determining the durability of the measured effects over long-term continuous use. Research is also ongoing to better define the medication's role when used alongside current widely accepted standard therapies, particularly for asthma.

How should Amitone be stored and disposed of?

Storage and Disposal of Amitone (Ketotifen Fumarate)

The official storage conditions for Amitone Ophthalmic Solution require keeping the product between 4 C and 25 C (39 F to 77 F), protecting it from freezing, direct light, and excess heat or moisture. The container must be kept tightly closed when not in use. After the initial opening of the multi-dose bottle, the solution is only stable for 28 days and must be discarded thereafter.

All medication, including Amitone, must be stored securely out of the sight and reach of children.

Disposal

Unused or expired medication should be disposed of using a drug take-back program when available. If not, it can be disposed of in the household trash after mixing it with an undesirable substance and sealing it in a plastic bag. The product should not be emptied into drains or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amitone found in:

A-Z Index: